Biotechnology agency Biogen Inc. (NASDAQ: BIIB) Thursday reported a year-over-year lower in adjusted revenue for the primary quarter of 2025, regardless of a rise in...
Biotechnology agency Biogen Inc. (NASDAQ: BIIB) reported decrease earnings, on an adjusted foundation, and revenues for the fourth quarter of 2023. Complete income declined 6%...